Literature DB >> 33572780

MicroRNAs in the Pathogenesis of Hepatocellular Carcinoma: A Review.

Asahiro Morishita1, Kyoko Oura1, Tomoko Tadokoro1, Koji Fujita1, Joji Tani1, Tsutomu Masaki1.   

Abstract

Hepatocellular carcinoma (HCC) is the seventh most frequent cancer and the fourth leading cause of cancer mortality worldwide. Despite substantial advances in therapeutic strategies, the prognosis of late-stage HCC remains dismal because of the high recurrence rate. A better understanding of the etiology of HCC is therefore necessary to improve outcomes. MicroRNAs (miRNAs) are small, endogenous, noncoding, single-stranded RNAs that modulate the expression of their target genes at the posttranscriptional and translational levels. Aberrant expression of miRNAs has frequently been detected in cancer-associated genomic regions or fragile sites in various human cancers and has been observed in both HCC cells and tissues. The precise patterns of aberrant miRNA expression differ depending on disease etiology, including various causes of hepatocarcinogenesis, such as viral hepatitis, alcoholic liver disease, or nonalcoholic steatohepatitis. However, little is known about the underlying mechanisms and the association of miRNAs with the pathogenesis of HCC of various etiologies. In the present review, we summarize the key mechanisms of miRNAs in the pathogenesis of HCC and emphasize their potential utility as valuable diagnostic and prognostic biomarkers, as well as innovative therapeutic targets, in HCC diagnosis and treatment.

Entities:  

Keywords:  biomarker; hepatocellular carcinoma; microRNA; pathogenesis; therapeutic target

Year:  2021        PMID: 33572780      PMCID: PMC7866004          DOI: 10.3390/cancers13030514

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  361 in total

1.  Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation.

Authors:  Zhong-Bo Han; Hong-Yuan Chen; Jun-Wei Fan; Jun-Yi Wu; Hua-Mei Tang; Zhi-Hai Peng
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-10       Impact factor: 4.553

2.  Combinatorial microRNA target predictions.

Authors:  Azra Krek; Dominic Grün; Matthew N Poy; Rachel Wolf; Lauren Rosenberg; Eric J Epstein; Philip MacMenamin; Isabelle da Piedade; Kristin C Gunsalus; Markus Stoffel; Nikolaus Rajewsky
Journal:  Nat Genet       Date:  2005-04-03       Impact factor: 38.330

3.  Clinical significance of microRNA-21 expression in disease progression of patients with hepatocellular carcinoma.

Authors:  Jun Sik Yoon; Gyeonghwa Kim; Yu Rim Lee; Soo Young Park; Won Young Tak; Young-Oh Kweon; Jung Gil Park; Hye Won Lee; Young Seok Han; Heon Tak Ha; Jae Min Chun; Se Young Jang; Keun Hur
Journal:  Biomark Med       Date:  2018-09-07       Impact factor: 2.851

4.  Expression profiling of serum microRNA-101 in HBV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.

Authors:  Yun Xie; Qinwei Yao; Azeem Mehmood Butt; Jia Guo; Zhou Tian; Xuli Bao; Hongxia Li; Qinghua Meng; Jun Lu
Journal:  Cancer Biol Ther       Date:  2014-06-27       Impact factor: 4.742

5.  MiR-892a Promotes Hepatocellular Carcinoma Cells Proliferation and Invasion Through Targeting CD226.

Authors:  Baoxing Jia; Ludong Tan; Zhe Jin; Yan Jiao; Yu Fu; Yahui Liu
Journal:  J Cell Biochem       Date:  2016-12-29       Impact factor: 4.429

6.  Primate-specific microRNA-637 inhibits tumorigenesis in hepatocellular carcinoma by disrupting signal transducer and activator of transcription 3 signaling.

Authors:  Jin-fang Zhang; Ming-liang He; Wei-ming Fu; Hua Wang; Lian-zhou Chen; Xiao Zhu; Ying Chen; Dan Xie; Paul Lai; Gong Chen; Gang Lu; Marie C M Lin; Hsiang-fu Kung
Journal:  Hepatology       Date:  2011-12       Impact factor: 17.425

7.  MicroRNA-302d downregulates TGFBR2 expression and promotes hepatocellular carcinoma growth and invasion.

Authors:  Yue-Liang Chen; Qiu-Ping Xu; Feng Guo; Wen-Hua Guan
Journal:  Exp Ther Med       Date:  2016-12-13       Impact factor: 2.447

8.  MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma.

Authors:  Wei-Chih Tsai; Paul Wei-Che Hsu; Tsung-Ching Lai; Gar-Yang Chau; Ching-Wen Lin; Chun-Ming Chen; Chien-Der Lin; Yu-Lun Liao; Jui-Ling Wang; Yat-Pang Chau; Ming-Ta Hsu; Michael Hsiao; Hsien-Da Huang; Ann-Ping Tsou
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

9.  miR-663a inhibits hepatocellular carcinoma cell proliferation and invasion by targeting HMGA2.

Authors:  Weizhen Huang; Jun Li; Xiaohong Guo; Yingchu Zhao; Xia Yuan
Journal:  Biomed Pharmacother       Date:  2016-04-28       Impact factor: 6.529

10.  miR-4417 Targets Tripartite Motif-Containing 35 (TRIM35) and Regulates Pyruvate Kinase Muscle 2 (PKM2) Phosphorylation to Promote Proliferation and Suppress Apoptosis in Hepatocellular Carcinoma Cells.

Authors:  Lijie Song; Weijie Zhang; Zhiwei Chang; Yanfeng Pan; Hong Zong; Qingxia Fan; Liuxing Wang
Journal:  Med Sci Monit       Date:  2017-04-10
View more
  14 in total

Review 1.  Animal Models of Hepatocellular Carcinoma for Local-Regional Intraarterial Therapies.

Authors:  Vishnu M Chandra; Luke R Wilkins; David L Brautigan
Journal:  Radiol Imaging Cancer       Date:  2022-07

2.  Cyanidin-3-Glucoside Modulates hsa_circ_0001345/miRNA106b/ATG16L1 Axis Expression as a Potential Protective Mechanism against Hepatocellular Carcinoma.

Authors:  Shaimaa Zabady; Nievin Mahran; Mohamed A Soltan; Muhammad Alaa Eldeen; Refaat A Eid; Sarah Albogami; Eman Fayad; Marwa Matboli; Eman K Habib; Amany H Hasanin; Mahmoud A Ali; Noha M Mesbah; Dina M Abo-Elmatty; Asmaa R Abdel-Hamed
Journal:  Curr Issues Mol Biol       Date:  2022-04-12       Impact factor: 2.976

3.  MicroRNA Expression Profiles in Superficial Esophageal Squamous Cell Carcinoma before Endoscopic Submucosal Dissection: A Pilot Study.

Authors:  Shintaro Fujihara; Hideki Kobara; Noriko Nishiyama; Kayo Hirose; Hisakazu Iwama; Tsutomu Masaki
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

4.  Plasma-Derived Exosome MiR-19b Acts as a Diagnostic Marker for Pancreatic Cancer.

Authors:  Lei Wang; Jinxiang Wu; Naikuan Ye; Feng Li; Hanxiang Zhan; Shihong Chen; Jianwei Xu
Journal:  Front Oncol       Date:  2021-09-13       Impact factor: 6.244

5.  miR-146b-5p promotes colorectal cancer progression by targeting TRAF6.

Authors:  Liangpan Shi; Yibin Su; Zhihua Zheng; Jinyu Qi; Weidong Wang; Cunchuan Wang
Journal:  Exp Ther Med       Date:  2022-01-20       Impact factor: 2.447

6.  Potential plasma biomarkers: miRNA-29c, miRNA-21, and miRNA-155 in clinical progression of Hepatocellular Carcinoma patients.

Authors:  Neneng Ratnasari; Puji Lestari; Dede Renovaldi; Juwita Raditya Ningsih; Nanda Qoriansas; Tirta Wardana; Suharno Hakim; Nur Signa Aini Gumilas; Fahmi Indrarti; Catharina Triwikatmani; Putut Bayupurnama; Didik Setyo Heriyanto; Indwiani Astuti; Sofia Mubarika Harjana
Journal:  PLoS One       Date:  2022-02-14       Impact factor: 3.240

Review 7.  Nucleic acid biomarkers to assess graft injury after liver transplantation.

Authors:  Elissa Bardhi; Jennifer McDaniels; Thomas Rousselle; Daniel G Maluf; Valeria R Mas
Journal:  JHEP Rep       Date:  2022-01-26

8.  miR‑374c‑5p regulates PTTG1 and inhibits cell growth and metastasis in hepatocellular carcinoma by regulating epithelial‑mesenchymal transition.

Authors:  Gang Yang; Yongfu Xiog; Guan Wang; Weinan Li; Tao Tang; Ji Sun; Jingdong Li
Journal:  Mol Med Rep       Date:  2022-03-02       Impact factor: 3.423

9.  Detection of exosomal miR-18a and miR-222 levels in Egyptian patients with hepatic cirrhosis and hepatocellular carcinoma.

Authors:  Eman A Elghoroury; Esmat E Abdelghaffar; Eman Awadallah; Solaf A Kamel; Dina Kandil; Eman M Hassan; Mirhane Hassan; Mahmoud M Kamel; Mohammed M Gomaa; Lamiaa A Fathalla
Journal:  Int J Immunopathol Pharmacol       Date:  2022 Jan-Dec       Impact factor: 3.298

10.  Transcription Factors and Methylation Drive Prognostic miRNA Dysregulation in Hepatocellular Carcinoma.

Authors:  Shijie Qin; Jieyun Xu; Yunmeng Yi; Sizhu Jiang; Ping Jin; Xinyi Xia; Fei Ma
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.